资讯

TMCnet14 小时
Piramal Pharma Limited Announces Results for Q4 and FY2025
MUMBAI, India, May 14, 2025 /CNW/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals ...
STAT15 小时
Prenatal genetic therapy for SMA shows promise in a mouse study
The scientists at the University of California, San Francisco and Johns Hopkins University in Baltimore injected an antisense ...
The Manila Times1 天
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
R&D Expenses: Research and development expenses for the quarter ended March 31, 2025, were $10.1 million, compared to $9.7 million for the quarter ended March 31, 2024. The increase in R&D expenses ...